MICHAEL E RYTTING to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications MICHAEL E RYTTING has written about Leukemia, Myeloid, Acute.
Connection Strength
0.368
-
Acute myeloid leukaemia masquerading as a primary CNS tumour. BMJ Case Rep. 2017 Aug 11; 2017.
Score: 0.145
-
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8.
Score: 0.091
-
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 11; 35(11):3282-3286.
Score: 0.047
-
Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606.
Score: 0.039
-
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22.
Score: 0.015
-
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
Score: 0.014
-
Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Pediatr Hematol Oncol. 1998 Sep-Oct; 20(5):516-7.
Score: 0.010
-
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64.
Score: 0.005
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.004